Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial

BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial

MT newswireMT newswire2026/09/15 11:42
07:42 AM EDT, 09/15/2026 (MT Newswires) -- BlossomHill Therapeutics (BLSM) said Tuesday that updated data from the phase 1/2 SOLARA trial of BH-30643 showed a 45% objective response rate and an 88% disease control rate in patients with EGFR C797S-positive non-small cell lung cancer following prior EGFR inhibitor treatment. Among 40 patients, 18 achieved a confirmed or ongoing unconfirmed partial response, while 25 remained on treatment at a median follow-up of 6.9 months, the company said. Among 174 patients treated at expansion doses of 40 mg, 50 mg or 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively, BlossomHill said. BlossomHill plans to initiate a global phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027. Shares of the company were 6.7% higher in Tuesday premarket activity.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Bank of Japan Governor: Wage growth is "quite strong," next year's spring shunto negotiations will be a key variable

The minutes of the Bank of Japan show that Governor Kazuo Ueda said recent wage growth has been "quite strong," in line with the 2% inflation target. Next year's wage negotiations and cost pass-through will be key factors for policy.

智通财经•2026/11/16 09:24
Bank of Japan Governor: Wage growth is "quite strong," next year's spring shunto negotiations will be a key variable